Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on developing clean, sustainable solutions for plastics, chemicals and energy, today announced that it has appointed Celeste Beeks Mastin to its board of directors. Ms. Mastin brings more than 20 years of experience in the global chemicals and performance materials sector to the Company’s board. The appointment is effective as of Thursday, January 19, 2012.
Richard P. Eno, president and CEO of Metabolix, commented, “Celeste has an impressive track record of accomplishment in the global chemicals and performance materials sector. We expect to benefit from her deep operating experience in sales and marketing and proven leadership ability as we develop and implement effective strategies to commercialize our leading-edge technology in both PHA bioplastics and renewable industrial chemicals.”
Ms. Mastin recently served as chief executive officer of MMI Products, Inc., where she had profit/loss responsibility for a $750 million building materials company with 18 manufacturing locations and 2,500 employees. Prior to MMI Products, she spent 17 years in the chemical industry. At Ferro Corporation, she held the role of vice president of Color and Glass Performance Materials, with profit/loss responsibility for a $400 million global business, and the role of vice president of growth and development. Ms. Mastin started her career in sales at Shell Chemical, where she served five years in sales positions of increasing responsibility. Her sales experience expanded at Bostik, Inc., where she held European and later global sales management positions, with her career at Bostik culminating in the role of vice president/general manager of Nonwovens, a $200 million global adhesives business. Ms. Mastin holds a bachelor’s degree in chemical engineering from Washington State University and a master’s degree in business administration from the University of Houston.
Ms. Mastin commented, “The increasing demand for bioplastics and renewable chemicals to meet the sustainable needs of businesses and consumers makes this a market poised for growth. Metabolix’s unique, proprietary technology platforms are among the most advanced in the industry and I am looking forward to joining the company’s board of directors and helping to position Metabolix for commercial success.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts